drugset
Drugs / C-188-9
last change Nov 2025 re-read 2 minutes ago

C-188-9

also known as TTI-101 · Stat3 inhibitor c188-9 · Stat3 inhibitor tti-101

Small molecule targets STAT3 via inhibition

Developed for
head and neck squamous cell carcinoma · hepatocellular carcinoma · breast cancer · colorectal cancer · female breast carcinoma · gastric adenocarcinoma · idiopathic pulmonary fibrosis · melanoma
+2 more · non-small cell lung carcinoma · pancreatic ductal adenocarcinoma
Investigated by
Tvardi Therapeutics, Incorporated · M.D. Anderson Cancer Center · National Institutes of Health (NIH) · The V Foundation · Washington University School of Medicine

Trials 7 · a red edge is where a trial was stopped

today NCT05668949 · Ph 1/2 NCT05845307 · Ph 0 NCT06141031 · Ph 1 NCT05671835 · Ph 2 NCT05440708 · Ph 1/2 NCT05384119 · Ph 1 NCT03195699 · Ph 1
201820192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT05845307 Jun → Nov 2025 head and neck squamous cell carcinoma M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 13 trials
Phase 1 NCT06141031 Jan 2024 → Jun 2029 expected pancreatic ductal adenocarcinoma Washington University School of Medicine Recruiting No outcome recorded
Phase 1 NCT05384119 Jan 2023 → Apr 2024 female breast carcinoma Tvardi Therapeutics, Incorporated Terminated No outcome recorded
Phase 1 NCT03195699 Nov 2017 → Jun 2024 breast cancer, colorectal cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma +3 Tvardi Therapeutics, Incorporated Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT05668949 Sep 2025 head and neck squamous cell carcinoma M.D. Anderson Cancer Center Withdrawn No outcome recorded
Phase 1/2 NCT05440708 Mar 2023 → Feb 2027 expected hepatocellular carcinoma Tvardi Therapeutics, Incorporated Recruiting No outcome recorded
Phase 21 trial
Phase 2 NCT05671835 May 2023 → Aug 2025 idiopathic pulmonary fibrosis Tvardi Therapeutics, Incorporated Completed No outcome recorded

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 9 sources stand behind the page.

FieldValueCited text
Known as C-188-9 ChEMBL registry synonym — accepted as the source's own label CHEMBL3392776 ↗
Known as Stat3 inhibitor c188-9 ChEMBL registry synonym — accepted as the source's own label CHEMBL3392776 ↗
Known as Stat3 inhibitor tti-101 ChEMBL registry synonym — accepted as the source's own label CHEMBL3392776 ↗
Known as TTI-101 ClinicalTrials.gov intervention name — accepted as the source's own label NCT06141031 ↗
6

NCT05845307 ↗

NCT05668949 ↗

NCT03195699 ↗

NCT05671835 ↗

NCT05440708 ↗

NCT05384119 ↗
Action Inhibit “direct inhibitor of STAT3” NCT03195699 ↗
Modality Small molecule “a first-in-class, selective small-molecule inhibitor of signal transducer and activator of transcription 3” PMID 39792482 ↗ Mar 2025
Route Oral “Patients were treated with TTI-101 orally twice daily” PMID 39792482 ↗ Mar 2025
Target STAT3 “a first-in-class, selective small-molecule inhibitor of signal transducer and activator of transcription 3” PMID 39792482 ↗ Mar 2025